---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-007867"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:39:15.299940+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunocore HIV cure candidate IMC-M113V shows dose-dependent viral control in Phase 1/2 MAD data at CROI 2025

## Summary
- Well tolerated across 60-300 mcg doses; no dose-limiting toxicities or serious AEs; mild CRS in 5 of 6 at 300 mcg.
- 3 of 15 evaluable PLWH showed delayed viral rebound or viremia control after ART interruption; 2 remained off ART for full 12 weeks.
- Dose-dependent reduction in active reservoir (CD4+ Gag RNA) and trend of intact HIV DNA reduction at higher doses.
- Enrollment continues with higher doses; expansion cohorts planned at one or more doses.
- IMC-M113V is first TCR bispecific targeting HIV in clinic, aims for functional cure.

## SEC filing metadata
- accession: 0001140361-25-007867
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036125007867/0001140361-25-007867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036125007867/ef20045169_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-007867
- JSON: https://secwatch.observer/filing/0001140361-25-007867.json
- Plain text: https://secwatch.observer/filing/0001140361-25-007867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.